TLR4 and metabolic dysfunction-associated steatohepatitis: Anti-TLR4 antibodies are now being tested in phase II studies for the treatment of rheumatoid arthritis, while the TLR4 inhibitor JKB-121 is being tested for the treatment of nonalcoholic steatohepatitis [328].